Summary
This study presents a critical analysis of the use of intravesical Epodyl in patients who had been having recurrences for a mean of 5.5 years after diagnosis and assesses its value particularly in patients with poor risk superficial bladder carcinoma. Epodyl was associated with a complete response rate of 32%, with the complete response lasting for a mean of 4.3 years to death or end of follow-up. It was ineffective in patients who initially had pT1 histology but was associated with a decrease in recurrence rate in patients who had large or multiple tumours at diagnosis. It was less effective in patients whose recurrence pattern after initial resection was continuous rather than intermittent. If a patient has not responded to Epodyl by 1 year, radical cystectomy should be carried out as soon as possible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbassian A, Wallace, DM (1966) Intracavitory chemotherapy of diffuse non-infiltrating papillary carcinoma of the bladder. J Urol 96:461
Fitzpatrick JM, Khan O, Oliver RTD, Riddle PR (1979) Long-term follow-up in patients with intravesical Epodyl. Br J Urol 51:545
Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD (1986) Superficial bladder tumours (pTa Grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135:920
Kurth KH, Maksimoni PA, Hop WCJ, Schröder FH, Bakker NJ (1983) Single-dose intravesical Epodyl after TUR of Ta TCC bladder carcinoma. World J Urol 1:89
Riddle PR, Wallace DM (1973) The management of superficial bladder tumours with intravesical Epodyl. Br J Urol 45:84
Riddle PR, Khan O, Fitzpatrick JM, Oliver RTD (1982) Prognostic factors influencing survival of patients receiving intravesical Epodyl. J Urol 127:430
Robinson MRG, Shetty MB, Richards B, Bastable J, Glashan RW, Smith PH (1977) Intravesical Epodyl in the management of bladder tumours: combined experience of the Yorkshire Urological cancer research group. J Urol 118:972
Smith JM, Lane V, O'Flynn JD (1978) Epodyl in the management of non-invasive vesical neoplasms. Urology 11:474
Schulman CC, Denis LJ, Oosterlinck W, DeSy W, Chantrie M, Bouffioux C, Von Cangh PJ, Von Erps P (1983) Early adjuvant Adriamycin in superficial bladder carcinoma. World J Urol 1:86
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fitzpatrick, J.M., West, A.B., Butler, M.R. et al. The role of adverse risk factors in response to epodyl treatment in superficial bladder cancer. World J Urol 4, 211–214 (1986). https://doi.org/10.1007/BF00326963
Issue Date:
DOI: https://doi.org/10.1007/BF00326963